7.03
price up icon3.53%   0.24
after-market After Hours: 6.98 -0.05 -0.71%
loading
Altimmune Inc stock is traded at $7.03, with a volume of 1.67M. It is up +3.53% in the last 24 hours and up +12.84% over the past month. Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.
See More
Previous Close:
$6.79
Open:
$6.76
24h Volume:
1.67M
Relative Volume:
0.78
Market Cap:
$499.63M
Revenue:
$409.00K
Net Income/Loss:
$-101.35M
P/E Ratio:
-4.3129
EPS:
-1.63
Net Cash Flow:
$-71.49M
1W Performance:
-4.48%
1M Performance:
+12.84%
6M Performance:
-3.70%
1Y Performance:
+156.57%
1-Day Range:
Value
$6.64
$7.03
1-Week Range:
Value
$6.45
$7.31
52-Week Range:
Value
$2.315
$14.84

Altimmune Inc Stock (ALT) Company Profile

Name
Name
Altimmune Inc
Name
Phone
(240) 654-1450
Name
Address
910 CLOPPER ROAD, GAITHERSBURG, MD
Name
Employee
59
Name
Twitter
Name
Next Earnings Date
2024-11-05
Name
Latest SEC Filings
Name
ALT's Discussions on Twitter

Altimmune Inc Stock (ALT) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-29-24 Downgrade Guggenheim Buy → Neutral
Jan-24-24 Initiated Goldman Neutral
Mar-22-23 Downgrade Goldman Buy → Neutral
Dec-01-22 Initiated Goldman Buy
Dec-29-21 Resumed Jefferies Buy
Jun-02-21 Initiated H.C. Wainwright Buy
Feb-11-21 Initiated Guggenheim Buy
Dec-14-20 Initiated Jefferies Buy
Nov-12-20 Reiterated B. Riley Securities Buy
Sep-25-20 Initiated B. Riley FBR Buy
Aug-14-20 Initiated Evercore ISI Outperform
Jul-31-20 Initiated Piper Sandler Overweight
Jul-28-20 Initiated JMP Securities Mkt Outperform
Feb-24-20 Resumed ROTH Capital Buy
Jul-19-19 Initiated ROTH Capital Buy
Oct-09-17 Initiated Piper Jaffray Overweight
View All

Altimmune Inc Stock (ALT) Latest News

pulisher
04:17 AM

Altimmune (ALT) to Release Quarterly Earnings on Tuesday - MarketBeat

04:17 AM
pulisher
Nov 04, 2024

Altimmune’s stock soars more than 40% after biopharma company says trial of obesity drug led to weight loss - MSN

Nov 04, 2024
pulisher
Nov 04, 2024

Altimmune to Report Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024 - StockTitan

Nov 04, 2024
pulisher
Oct 30, 2024

Thinking about buying stock in Minim, Aurora Innovation, Altimmu - GuruFocus.com

Oct 30, 2024
pulisher
Oct 30, 2024

Altimmune Awaits Results Of Fatty Liver Disease Drug Pemvidutide - RTTNews

Oct 30, 2024
pulisher
Oct 29, 2024

Altimmune (NASDAQ:ALT) Trading Up 7%Here's What Happened - MarketBeat

Oct 29, 2024
pulisher
Oct 29, 2024

Altimmune (ALT) Price Target Increased by 9.39% to 19.53 - MSN

Oct 29, 2024
pulisher
Oct 28, 2024

Regulatory And Clinical Catalysts Ahead For Altimmune (NASDAQ:ALT) - Seeking Alpha

Oct 28, 2024
pulisher
Oct 26, 2024

When (ALT) Moves Investors should Listen - Stock Traders Daily

Oct 26, 2024
pulisher
Oct 25, 2024

Altimmune, Inc. Securities Fraud Class Action Lawsuit Pending: C - GuruFocus.com

Oct 25, 2024
pulisher
Oct 25, 2024

Altimmune Jumps 66% After Positive Results for Its Obesity Drug - MSN

Oct 25, 2024
pulisher
Oct 24, 2024

Altimmune, Inc. (NASDAQ:ALT) Receives $18.80 Average Target Price from Brokerages - MarketBeat

Oct 24, 2024
pulisher
Oct 23, 2024

SG Americas Securities LLC Sells 220,135 Shares of Altimmune, Inc. (NASDAQ:ALT) - MarketBeat

Oct 23, 2024
pulisher
Oct 17, 2024

State Street Corp's Strategic Reduction in Altimmune Inc Holdings - Yahoo Finance

Oct 17, 2024
pulisher
Oct 17, 2024

Altimmune, Inc. (ALT): A Bull Case Theory - MSN

Oct 17, 2024
pulisher
Oct 17, 2024

Exchange Traded Concepts LLC Has $1.33 Million Position in Altimmune, Inc. (NASDAQ:ALT) - MarketBeat

Oct 17, 2024
pulisher
Oct 16, 2024

Millennium Management LLC Increases Stake in Altimmune Inc - Yahoo Finance

Oct 16, 2024
pulisher
Oct 15, 2024

Altimmune (NASDAQ:ALT) Trading Up 10.7%Should You Buy? - MarketBeat

Oct 15, 2024
pulisher
Oct 15, 2024

Learn to Evaluate (ALT) using the Charts - Stock Traders Daily

Oct 15, 2024
pulisher
Oct 15, 2024

Altimmune to Present New Data on the Lipidomic Profile in Subjects Treated with Pemvidutide at The Liver Meeting® 2024 - The Manila Times

Oct 15, 2024
pulisher
Oct 10, 2024

Altimmune, Inc. (NASDAQ:ALT) Shares Acquired by Dimensional Fund Advisors LP - MarketBeat

Oct 10, 2024
pulisher
Oct 09, 2024

Altimmune Inc (ALT) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - Yahoo Finance

Oct 09, 2024
pulisher
Oct 09, 2024

Altimmune Inc (ALT) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges By GuruFocus - Investing.com Canada

Oct 09, 2024
pulisher
Oct 04, 2024

Where are the Opportunities in (ALT) - Stock Traders Daily

Oct 04, 2024
pulisher
Oct 02, 2024

Consider Buying Potential Takeover Target Altimmune (NASDAQ:ALT) - Seeking Alpha

Oct 02, 2024
pulisher
Oct 01, 2024

Altimmune to Participate in the H.C. Wainwright 8th Annual MASH Virtual Conference - The Manila Times

Oct 01, 2024
pulisher
Sep 30, 2024

Altimmune completes enrollment for MASH treatment trial By Investing.com - Investing.com South Africa

Sep 30, 2024
pulisher
Sep 30, 2024

Altimmune completes enrollment for MASH treatment trial - Investing.com India

Sep 30, 2024
pulisher
Sep 30, 2024

Altimmune Completes Enrollment in Phase 2b IMPACT Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH) - The Manila Times

Sep 30, 2024
pulisher
Sep 30, 2024

Altimmune, Inc. Completes Enrollment in Phase 2B Impact Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis - Marketscreener.com

Sep 30, 2024
pulisher
Sep 29, 2024

Altimmune, Inc. (NASDAQ:ALT) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat

Sep 29, 2024
pulisher
Sep 28, 2024

Profund Advisors LLC Sells 94,081 Shares of Altimmune, Inc. (NASDAQ:ALT) - MarketBeat

Sep 28, 2024
pulisher
Sep 27, 2024

Wall Street SWOT: Altimmune stock rides wave of promising obesity drug data - Investing.com

Sep 27, 2024
pulisher
Sep 24, 2024

Logos Global Management LP Sells 750,000 Shares of Applied Therapeutics, Inc. (NASDAQ:APLT) - Defense World

Sep 24, 2024
pulisher
Sep 24, 2024

Altimmune Inc [ALT] Investment Guide: What You Need to Know - Knox Daily

Sep 24, 2024
pulisher
Sep 24, 2024

Farallon Capital Management LLC Has $184,000 Stake in Altimmune, Inc. (NASDAQ:ALT) - MarketBeat

Sep 24, 2024
pulisher
Sep 24, 2024

SEC Form FWP filed by Alta Global Group Limited - Quantisnow

Sep 24, 2024
pulisher
Sep 24, 2024

How the (ALT) price action is used to our Advantage - Stock Traders Daily

Sep 24, 2024
pulisher
Sep 24, 2024

Unique Fabricating (NYSEAMERICAN:UFAB) Trading Down 17.6% - Defense World

Sep 24, 2024
pulisher
Sep 23, 2024

StockWatch: FDA Surprise Lifts Expectations for Applied’s Govorestat - Genetic Engineering & Biotechnology News

Sep 23, 2024
pulisher
Sep 21, 2024

Altimmune: Updated Data Supports Pemvidutide's 'Market Disruptor' Prospects (NASDAQ:ALT) - Seeking Alpha

Sep 21, 2024
pulisher
Sep 20, 2024

Altimmune (NASDAQ:ALT) Trading Up 3.7% - MarketBeat

Sep 20, 2024
pulisher
Sep 20, 2024

Milan Fashion Week: At Gucci, making fashion wearable - CNA Luxury

Sep 20, 2024
pulisher
Sep 20, 2024

The Best Celebrity Shoes at Gucci’s Spring 2025 Show in Milan: Kirsten Dunst, Lucky Blue Smith, Nara Smith and More - Footwear News

Sep 20, 2024
pulisher
Sep 20, 2024

"Commit To It and Do It": Mel and Lyas Gather the Girls for a Gucci SS25 Debrief - Interview

Sep 20, 2024
pulisher
Sep 20, 2024

Take a look at celebrities' outfits for Milan Fashion Week's Gucci show - Marca English

Sep 20, 2024
pulisher
Sep 20, 2024

Sabato swings into the sixties: What went down at Gucci SS25 - Dazed

Sep 20, 2024
pulisher
Sep 20, 2024

TikTok Star Nara Smith Stuns at Gucci’s Spring 2025 Show in Patent Leather Signoria Slingback Pumps at Milan Fashion Week - Yahoo Entertainment

Sep 20, 2024
pulisher
Sep 19, 2024

Applied Therapeutics stock surges after FDA update - The Pharma Letter

Sep 19, 2024
pulisher
Sep 19, 2024

Altimmune (NASDAQ:ALT) Trading Down 4.5% - MarketBeat

Sep 19, 2024
pulisher
Sep 17, 2024

Prediction: This Will Be the First Healthcare Stock to Join the Trillion-Dollar Club - The Motley Fool

Sep 17, 2024

Altimmune Inc Stock (ALT) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Altimmune Inc Stock (ALT) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Drutz David
Director
Aug 19 '24
Sale
6.90
16,011
110,547
41,958
Roberts M Scot
Chief Scientific Officer
Feb 02 '24
Option Exercise
0.00
7,775
0
44,990
Roberts M Scot
Chief Scientific Officer
Feb 01 '24
Option Exercise
0.00
6,166
0
39,016
Harris Matthew Scott
Chief Medical Officer
Feb 02 '24
Option Exercise
0.00
7,775
0
55,965
Harris Matthew Scott
Chief Medical Officer
Feb 01 '24
Option Exercise
0.00
6,166
0
49,991
Garg Vipin K
President and CEO
Feb 02 '24
Option Exercise
0.00
18,950
0
300,404
Garg Vipin K
President and CEO
Feb 01 '24
Option Exercise
0.00
16,545
0
288,767
Roberts M Scot
Chief Scientific Officer
Jan 30 '24
Option Exercise
0.00
9,275
0
29,699
Harris Matthew Scott
Chief Medical Officer
Jan 30 '24
Option Exercise
0.00
9,275
0
43,277
Garg Vipin K
President and CEO
Jan 30 '24
Option Exercise
0.00
26,775
0
276,030
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
Cap:     |  Volume (24h):